616 related articles for article (PubMed ID: 36380085)
1. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.
Yin Y; Shu Y; Zhu J; Li F; Li J
Sci Rep; 2022 Nov; 12(1):19555. PubMed ID: 36380085
[TBL] [Abstract][Full Text] [Related]
2. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system.
Shu Y; Ding Y; Dai B; Zhang Q
Expert Opin Drug Saf; 2022 Apr; 21(4):563-572. PubMed ID: 34918584
[TBL] [Abstract][Full Text] [Related]
3. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
[TBL] [Abstract][Full Text] [Related]
4. Post-marketing safety of anti-IL-5 monoclonal antibodies (mAbs): an analysis of the FDA Adverse Event Reporting System (FAERS).
Zou SP; Yang HY; Ouyang M; Cheng Q; Shi X; Sun MH
Expert Opin Drug Saf; 2024 Mar; 23(3):353-362. PubMed ID: 37610085
[TBL] [Abstract][Full Text] [Related]
5. Post-Marketing Safety Concerns with Upadacitinib: A Disproportionality Analysis of the FDA Adverse Event Reporting system.
Wu XP; Lu XK; Wang ZT; Huang L; Cai RW; Yu HM; Li JY; Xiao J
Expert Opin Drug Saf; 2023; 22(10):975-984. PubMed ID: 37310063
[TBL] [Abstract][Full Text] [Related]
6. A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS).
Zou SP; Yang HY; Ouyang ML; Cheng Q; Shi X; Sun MH
BMC Pharmacol Toxicol; 2023 Nov; 24(1):62. PubMed ID: 37957717
[TBL] [Abstract][Full Text] [Related]
7. Data mining and analysis of adverse event signals associated with teprotumumab using the Food and Drug Administration adverse event reporting system database.
Zhang S; Wang Y; Qi Z; Tong S; Zhu D
Int J Clin Pharm; 2024 Apr; 46(2):471-479. PubMed ID: 38245664
[TBL] [Abstract][Full Text] [Related]
8. Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System.
Huang J; Meng L; Yang B; Sun S; Luo Z; Chen H
Sci Rep; 2020 Mar; 10(1):4803. PubMed ID: 32179761
[TBL] [Abstract][Full Text] [Related]
9. Adverse events associated with immune checkpoint inhibitors in non-small cell lung cancer: a safety analysis of clinical trials and FDA pharmacovigilance system.
Liang X; Xiao H; Li H; Chen X; Li Y
Front Immunol; 2024; 15():1396752. PubMed ID: 38745663
[TBL] [Abstract][Full Text] [Related]
10. Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system.
Shu Y; Chen J; Ding Y; Zhang Q
Front Immunol; 2023; 14():1169735. PubMed ID: 37256136
[TBL] [Abstract][Full Text] [Related]
11. Adverse events of guselkumab in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system.
Xiang DC; Chen W; Fu ZW; Wu XH; Gao P; Wu Y
Expert Opin Drug Saf; 2023; 22(10):943-955. PubMed ID: 37294594
[TBL] [Abstract][Full Text] [Related]
12. A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib.
Guo M; Shu Y; Chen G; Li J; Li F
Sci Rep; 2022 Nov; 12(1):20601. PubMed ID: 36446798
[TBL] [Abstract][Full Text] [Related]
13. A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database.
Sun R; Ning Z; Qin H; Zhang W; Teng Y; Jin C; Liu J; Wang A
Sci Rep; 2024 Apr; 14(1):9552. PubMed ID: 38664423
[TBL] [Abstract][Full Text] [Related]
14. Post-Marketing Safety of Vemurafenib: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System.
Liu Y; Dong C; He X; Shu Y; Wu P; Zou J
J Pharm Pharm Sci; 2022; 25():377-390. PubMed ID: 36608646
[TBL] [Abstract][Full Text] [Related]
15. Data mining and safety analysis of avatrombopag: a retrospective pharmacovigilance study based on the US food and drug administration's adverse event reporting system.
Zhu H; Wu M
Sci Rep; 2024 May; 14(1):11262. PubMed ID: 38760419
[TBL] [Abstract][Full Text] [Related]
16. A real‑world pharmacovigilance study of FDA adverse event reporting system events for daratumumab.
Yun X; Zhou Y; Wu D; Liu Y; Wu Q
Expert Opin Drug Saf; 2024 May; 23(5):581-591. PubMed ID: 38600747
[TBL] [Abstract][Full Text] [Related]
17. A real-world pharmacovigilance study of abaloparatide based on the FDA Adverse Event Reporting System (FAERS).
Shi X; Cheng Q; Zhao YZ; Zou SP; Sun MH
Osteoporos Int; 2023 Dec; 34(12):2047-2058. PubMed ID: 37594595
[TBL] [Abstract][Full Text] [Related]
18. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
19. Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system.
Chen JJ; Huo XC; Wang SX; Wang F; Zhao Q
Int J Clin Pharm; 2022 Dec; 44(6):1351-1360. PubMed ID: 36178607
[TBL] [Abstract][Full Text] [Related]
20. Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS.
Ji HH; Tang XW; Dong Z; Song L; Jia YT
Clin Drug Investig; 2019 Mar; 39(3):319-330. PubMed ID: 30674039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
